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Homogeneous Markov Processes For Breast Cancer Analysis
Ricardo Ocaña- Riola

Emilio Sanchez- Cantalejo

Carmen Martinez- Garcia
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Sometimes, the introduction of covariates in stochastic processes is required to study their effect on disease
history events. However these types of models increase the complexity of analysis, even for simpler processes,
and standard software to analyse stochastic processes is limited. In this paper, a method for fitting homogeneous
Markov models with covariates is proposed for analysing breast cancer data. Specific software for this purpose
has been implemented.
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Introduction
In multivariate studies, the use of models
that incorporate covariates allows analysis of the
effect of these variables on the outcome variable.
When multi-state models are used, it is also possible
to study the effect of these covariates on different
transitions between states throughout the patient’s
disease history.
Some authors have worked on the
introduction of covariates in multi-state processes
and particularly in homogeneous Markov processes
(Kalbfleisch & Lawless, 1985; Pastorello, 1993);
however, they mentioned the increased comple xity
of analysis in this sort of model where an added
problem is the shortage of standard software. In
spite of these problems, the introduction of
covariates in stochastic processes is required to
explain the effect of these factors on disease history
events.
In this paper we present a breast cancer
study where two transient states and a death state
have been defined. In this study, observation is
continuous, i.e., information on exact transition
times between transient states is available; in this
context, the main objectives of this paper are:

Multi-state Markov processes have been introduced
recently in health sciences in order to study the
evolution of patients through different states or
stages before death, even in cases where exact
transition times are not known (Kay, 1986). This
type of model has been mainly applied in AIDS (De
Gruttola & Lagakos, 1989; Frydman, 1992;
Mariotto et al., 1992), cancer (Kay, 1986), and
psychiatric research (Keiding & Andersen, 1989),
employing different methodologies depending on
the particular conditions of each study. In practice, it
is often useful to use a homogeneous Markov
process to model disease history events because
generally they are easy to interpret and the
assumption that the process is homogeneous
simplifies the methods used to fit the model.
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Cuesta del Observatorio, 4 Apdo de Correos 2070
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España of the Ministerio de Educación y Ciencia.
The authors would like to thank Dr. Jacques Estève
and Angela Maldonado García.

a) To propose a method, computationally tractable,
to estimate homogeneous Markov models with
covariates in continuous time.
b) To study the evolution of patients diagnosed with
breast cancer in Granada province (South of Spain).

210

211

MARKOV PROCESSES FOR BREAST CANCER
Q(x) =
Methodology

The study was carried out with 241 women with
breast cancer diagnosed in 1985-86 who received
radical treatment and had a period free of symptoms.
The follow-up ended on 31 of December 1990
(Ocaña-Riola, 2002). Data originated from the
Granada Cancer Registry (South of Spain).
The variables T, N and Hormonal Status
(HS) on the disease history of individuals have been
recorded. The definition of T and N was taken from
the Classification of Malignant Tumours (Sobin and
Wittekind, 1997), where these variables are two
components of the TNM system for describing the
anatomical extent of disease. Variable M was not
considered because there were no patients with
distant metastasis. Additional numbers on TNM
components indicates the extent of the malignant
tumour as follows:
a) T: The extent of primary tumour; T0: No
evidence of primary tumour; T1: Tumour 2 cm or
less in greatest dimension; T2: Tumour more than 2
cm but not more than 5 cm in greatest dimension;
T3: Tumour more than 5 cm in greatest dimension;
T4: Tumour of any size with direct extension to
chest wall or skin.
b) N: The absence or presence and extent of regional
lymph node metastasis; N0: No regional lymph
node metastasis; N1: Metastasis to movable
ipsilateral axilla ry nodes(s); N2: Metastasis to
ipsilateral axillary node(s) fixed to one another or to
other structures; N3: Metastasis to ipsilateral internal
mammary lymph node(s).
It is considered to be a three-state Markov
model with two transient states and one absorbing
(Chiang, 1968). These states are “With symptoms “
(state 1), “Without symptoms “ (state 2) and
“Death “ (state 3) where the possible transitions are
represented in Figure 1 in appendix.
We consider the transition intensity matrix:

q12(x) q13(x) 
 -( q12(x)+ q 13(x))


q21(x) -( q 21(x)+ q 23(x)) q 23(x)




0
0
0


where each transition intensity is dependent on a
vector of covariates; that is:

q ij (x)= exp(x β i′j ) i ≠ j
q i (x)= ∑ exp(x β i′j ) ,
j ≠i

where x = ( x 0 ,..., xb ) , x0 =1, is a vector of
covariates and β ij = ( β ij0 ,..., β i′jb) is a vector of
unknown parameters.
In order to estimate the model an
approximate method was used (Ocaña-Riola,
2002). The Likelihood Ratio Statistic (LRS) was
used in a backward analysis to test the
signification of regression parameters (De Groot,
1986). Moreover, the LRS test was used for the
goodness of fit of the final model (Kalbfleisch &
Lawless, 1985). When the transition intensity
matrix is estimated, the estimated transition
probability matrix is P(u; x)=exp(Q(x)u), u>0.
Results
In order to estimate the model, we used a partition of
the time using 35 intervals which extent was
between 0.002 and 0.260 years (Figure 2 in
appendix). Because of shortage of subjects in the
groups N2 and N3 (Table 1), the variable N has
been transformed in a binary variable as N 1 = 0 if
N=0 and N 1 = 1 if N=1, N=2 or N=3.
There were not transitions from state 2 to
state 3 in Non-menopause patients, however there
are some in the Menopause group; if we interpret 23 as the transition to other causes of death, the
transitions observed in Menopause group could be
due to an age effect because older women heavily
weight this group. For this reason we propose the
following model:
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q 23 = exp( β230 + β231 T 2 + β 232 T 3+ β 233 T 4
+ β 234 N 1 )if H S = 1
q 23 = 0if HS=0
q 23 = exp( β230 + β231 T 2 + β 232 T 3+ β 233 T 4
+ β 234 N 1 )if H S = 1
q 23 = 0if HS=0
where T 2 ,T 3 , T 4 are dummy variables from T (T1
is the category of reference).
A backward analysis using LRS test
showed that variable N is not statistically significant
when T and HS are into the model (P=0.482).
Besides, there is no evidence (P=0.370) against the
codification of T in only two categories: patients
with a better prognosis (T1 or T2) and patients with
a bad prognosis (T3 or T4). Therefore it was
considered a new covariable, TR, with value 0 for
T1 or T2 and value 1 for T3 or T4. The final model
is shown in Table 2. MLE’s for transition intensities
in different groups of covariates are in Table 3.
Figures 3 and 4 show these transition
probabilities by groups of covariates. These graphs
show a notable difference between T1-T2 and T3T4. A LRS test for the goodness of fit of the final
model shows that there is no evidence against a
homogeneous Markov process (p=0.177).
Conclusion
Multi-state Markov models offer some advantages
over traditional survival models for studying disease
history events, making it possible to estimate the
probability that a subject could be in different states
at any time in the future. Homogeneous processes
are the simplest of Markov models but in some
studies it is possible to find evidence against this
sort of model. The absence of homogeneity in time
could be the result of the absence of homogeneity
between people. In this case, the use of covariates
could improve the fit of the model and
homogeneous Markov models with covariates are an
interesting option.
However, the incorporation of covariates in
a stochastic process increases the complexity of
analysis, even on simple processes. Because of that
and the shortage of standard software to analyse
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Markov process with incomplete observations,
many researchers refuse to use these multi-state
models. In spite of these problems, some authors
worked on the inclusion of covariates in a
homogeneous Markov process (Andersen, 1988;
Pastorello, 1993; Tuma & Robins, 1990). The more
used methods are based on the extended Kalbfleisch
and Lawless algorithm to incorporate covariates
(Kalbfleisch & Lawless, 1985).
In this article we have used a particular
partition of the time when observation is continuous.
In this situation an approximate method has been
proposed in order to introduce covariates and to
estimate the intensity matrix in a homogeneous
Markov process (Ocaña -Riola, 2002). MLE’s
obtained from this method are not computationally
costly and, in practice, the algorithm converges to
very similar estimates of parameters given by other
methods when the length of the intervals u k 1 tends
to be small (Ocaña -Riola, 2002). Moreover,
covariates can easily be introduced in the model.
The method proposed here consider only
categorical covariates because this is the sort of
variables analysed in the breast cancer study.
Continuous covariables, as age, could be introduced
in the analysis using different categories for them.
This idea has been used in some research about
stochastic processes and in practice it is the most
used (Tuma & Robins, 1980; Pastorello, 1993).
In this breast cancer study, incorporation of
variables T, N and Hormonal Status in the model
have allowed us to evaluate its effects on disease
history. However, covariate information was
missing for 36 women not included in the analysis.
In general, it is not a good statistical practice to
leave out patients with missing values; therefore
different statistical methods have been published
recently in order to incorporate these patients into
the analysis. Some authors have shown that using a
Bayesian approach implemented via Markov Chain
Monte Carlo it is possible to obtain a suitable
regression model for the missing values
(Raghunathan & Siscovick, 1996).
Due to the complexity of the Bayesian
analysis in a Markov process with covariates, we
have not implemented this method. However, it
would an interesting research into stochastic
processes.
Along these lines, Volinksy et al. (1997)
applied Bayesian Model Averaging to the selection
of variables in Cox proportional hazard models.
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Their investigations into the risk factors for strokes
using this model improve the results obtained by
traditional stepwise, forward and backward selection
methods, which have poor properties (Miller, 1990).
Again, the implementation of Bayesian Statistics
into Markov processes could yield interesting
results, although some theoretical research is needed
before using these methods in practice.
In a traditional backward analysis a
relationship was found between T and Hormonal
Status and the evolution of patients diagnosed with
breast cancer. Non-menopausal women with a
tumour T1 or T2 have the best prognosis since
recurrence probability and death probability are the
smallest. In the same way and using traditional
survival models, other population base studies have
found that both, T and Hormonal Status, are
important factors in order to predict survival and
recurrence probability in breast cancer (Coebergh et
al., 1995). Other analytic factors and hormonal data,
not included in this study, could explain to a great
extent part of breast cancer survival and recurrence.
Vascular and lymphatic invasion of cancer cells,
type of histology, age, site of first recurrence, female
sex steroid receptors and ploidy measurements have
been reported in some articles as prognostic factors
for breast cancer recurrence (Blanco G et al., 1990;
Murayama et al., 1986). In this way, a prospective
study could be interesting in order to analyse the
effect of all these variables on the evolution of
patients through different states of their disease,
obtaining a complete and detailed study on breast
cancer history.
In this study, the interpretation of the
transition from “without symptoms “ to “death “ is
difficult in menopausal women. Older women
heavily weight this group and perhaps the effect of
age can explain this situation. It might be interesting
to consider a fourth state “death from other causes “
in order to know the proportion of patients dying
from the direct or indirect consequences of breast
cancer but unfortunately this information is rarely
available in the Granada Cancer Registry.
From this paper’s findings, it will be
possible to estimate the proportions of patients who
shall be in each disease state in the future; therefore
we will be able to obtain highly relevant information
for health planning services. Furthermore, the
proposed method can easily be used for other
situations in cancer and other disciplines such as

public health, economics, sociological research or
medical sciences.
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Table 1. Breast cancer data. Granada Cancer Registry, 1985-1986.
Non-menopause

Menopause

N0

N1

N2

N3

Total

N0

N1

N2

N3

Total

T1
T2
T3
T4

15
20
1
2

8
7
5
7

0
1
1
0

0
0
0
0

23
28
7
9

29
41
7
4

6
21
4
15

0
3
1
2

0
0
2
3

35
65
14
24

Total

38

27
2
0
67
81
46
6
Note: There were 36 patients with missing values.

5

138

Table 2. MLE’s estimates for breast cancer data (standard error in brackets)
Transition (ij)

Constant ( β ij0 )

TR ( β ij1 )

Hormonal Status ( β ij2 )

1-2

*

-0.4665 (0.0108)

0.3321 (0.0067)

1-3

-1.7584 (0.0203)

*

0.5802 (0.0235)

2-1

-2.7298 (0.0169)

0.7570 (0.0166)

0.4442 (0.0183)

2-3

-3.7965 (0.0219)

*

No included

(*) Null statistical significance for α = 0.05

Table 3. Estimated transition intensities for breast cancer data.
T

Hormonal Status

qˆ 12

qˆ 13

qˆ 21

qˆ 23

T1 or T2
T1 or T2
T3 or T4
T3 or T4

Non-menopause
Menopause
Non-menopause
Menopause

1.0000
1.3939
0.6272
0.8742

0.1723
0.3078
0.1723
0.3078

0.0652
0.1017
0.1391
0.2168

0
0.0224
0
0.0224

